Education
About Us
Working with TipRanks
Follow Us
BioLineRX Ltd. (IL:BLRX)
:BLRX
Top Page
Bioline Rx
(BLRX)
Rating:51Neutral
Price Target:
2.50
▲(31.58%Upside)
Bioline Rx (BLRX) vs. iShares MSCI Israel ETF (EIS)
Market Cap
66.50M
Dividend YieldN/A
Average Volume (3M)16.07M
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth90.65%
EPS Growth90.80%
CountryIL
Employees28
SectorHealthcare
Sector Strength40
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,557,611,000
10 Day Avg. Volume7,950,613
30 Day Avg. Volume16,070,949
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-1.30
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue0.46
Enterprise Value/Gross Profit1.84
Enterprise Value/Ebitda-0.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bioline Rx Business Overview & Revenue Model
Company DescriptionBioLine Rx (BLRX) is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of unmet medical needs. The company focuses primarily on oncology and other significant medical conditions. BioLine Rx's core products include therapies in various stages of clinical trials, targeting diseases such as cancer and fibrotic disorders. The company's mission is to improve patients' lives by advancing breakthrough biomedical innovations from discovery to commercialization.
How the Company Makes MoneyBioLine Rx generates revenue primarily through strategic collaborations, licensing agreements, and the potential commercialization of its drug candidates. The company partners with pharmaceutical and biotechnology companies, leveraging these relationships to co-develop products and share resources. Revenue streams may include upfront payments, milestone payments based on the achievement of specific development or regulatory goals, and royalties on sales if the partnered products receive market approval. Additionally, BioLine Rx may receive funding from grants or government support for its research initiatives. These collaborations and agreements are critical to financing the company's operations and advancing its drug development pipeline.
Bioline Rx Earnings Call Summary
Earnings Call Date:May 27, 2025
(Q1-2025)
| % Change Since: -13.64%|
Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment Positive
The earnings call reflected a positive sentiment with multiple strategic milestones achieved, including successful out-licensing deals and a significant reduction in operating expenses. The company also demonstrated financial stability and progress in clinical trials. However, decreased revenues and potential challenges in regulatory approval for pancreatic cancer were noted as concerns.Q1-2025 Updates
Positive Updates
Successful Out-Licensing of APHEXDA
BioLineRx entered into an exclusive out-licensing agreement with Ayrmid Pharma Limited for APHEXDA, which is FDA-approved for stem cell mobilization. This agreement includes substantial commercial milestones and royalties.
Significant Reduction in Operating Expenses
BioLineRx reduced its operating cash burn by over 70%, from $40 million annually to less than $12 million, following the restructuring and out-licensing agreement with Ayrmid.
Financial Stability and Strong Cash Position
The company ended the first quarter of 2025 with $26.4 million in cash, a strong financial footing, and a cash runway expected to fund operations through the second half of 2026.
Encouraging APHEXDA Sales
APHEXDA generated $1.4 million in sales in Q1 2025, resulting in $0.3 million in royalty revenues for BioLineRx after returning to growth under Ayrmid's stewardship.
Promising Developments in Pancreatic Cancer Trial
Motixafortide showed a 64% response rate in a pilot study for pancreatic cancer, with new data to be presented at ASCO 2025. This compares favorably to historical response rates.
Negative Updates
Decreased Revenue
Total revenues for the quarter ended March 31, 2025, were $0.3 million compared to $6.9 million for the same period in 2024, primarily due to a decrease in upfront payments and milestone achievements.
Potential Challenges in Regulatory Approval for PDAC
The current pancreatic cancer trial may not lead to regulatory approval due to PFS being the primary endpoint instead of overall survival.
Company Guidance
During the BioLineRx First Quarter 2025 Financial Results Conference Call, Philip Serlin, CEO of BioLineRx, provided detailed guidance on the company's strategic focus and financial position. He highlighted the exclusive out-licensing agreement with Ayrmid Pharma Limited for APHEXDA, an FDA-approved stem cell mobilization agent, which generated $1.4 million in sales in Q1 2025, resulting in $0.3 million in royalty revenue for BioLineRx. The company's operating cash burn was significantly reduced by over 70% to less than $12 million annually, as a result of restructuring efforts, and they ended the quarter with $26.4 million in cash. They are focusing on evaluating early-stage oncology and rare disease assets to expand their pipeline, with potential funding from milestones and royalties from agreements with Ayrmid and Gloria Bio. The company also reported promising developments in ongoing trials, including two Phase 1 trials for sickle cell disease and a Phase 2b pancreatic cancer trial, with interim analysis expected in 2026.Bioline Rx Financial Statement Overview
Summary
BioLineRx is experiencing revenue growth, which is a positive indicator of potential market demand. However, the company faces significant challenges in profitability and cash flow management. High leverage and negative equity returns highlight financial instability. Continued operational inefficiencies and negative cash flow could pose risks if not addressed. Overall, while there are growth opportunities, financial risks remain prevalent.Income Statement
The company showed a significant increase in total revenue from 2023 to 2024, which is a positive sign of growth. However, the net profit margin remains negative due to substantial net losses, indicating ongoing financial challenges. The EBIT and EBITDA margins are also negative, reflecting inefficiencies in operations. Overall, while revenue growth is promising, profitability remains a concern.20
Very Negative
Balance Sheet
The debt-to-equity ratio increased, indicating higher leverage, which could be risky. The return on equity remains negative due to net losses, pointing to poor returns for shareholders. The equity ratio has decreased, suggesting reduced financial stability. Although the company has a strong asset base, the increased liabilities and negative equity returns are significant weaknesses.35
Negative
Cash Flow
The operating cash flow is negative, underscoring cash flow challenges. Free cash flow has also significantly declined, reflecting poor cash management. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income into cash. Despite some cash inflows from financing activities, the company struggles to generate positive cash flow, which could hinder its ability to fund operations.25
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.94M | 4.80M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 19.68M | 1.11M | 0.00 | 0.00 | 0.00 |
| EBITDA | 3.92M | -57.09M | -28.50M | -24.07M | -22.34M |
| Net Income | -9.22M | -60.61M | -20.75M | -28.14M | -30.93M |
Balance Sheet | |||||
| Total Assets | 38.91M | 63.92M | 76.38M | 81.39M | 47.29M |
| Cash, Cash Equivalents and Short-Term Investments | 19.56M | 42.99M | 51.08M | 57.13M | 22.59M |
| Total Debt | 15.04M | 11.59M | 12.32M | 4.65M | 7.68M |
| Total Liabilities | 25.45M | 50.70M | 25.54M | 13.30M | 25.26M |
| Stockholders Equity | 13.46M | 13.22M | 50.84M | 68.09M | 22.03M |
Cash Flow | |||||
| Free Cash Flow | -43.93M | -22.91M | -26.56M | -23.67M | -23.21M |
| Operating Cash Flow | -43.87M | -22.61M | -26.24M | -23.57M | -23.21M |
| Investing Cash Flow | 29.37M | 1.44M | 4.01M | -38.22M | 16.67M |
| Financing Cash Flow | 20.66M | 15.06M | 20.44M | 57.75M | 17.87M |
Bioline Rx Technical Analysis
Negative
1.90
Price Trends
2.29
Positive
2.14
Positive
5.79
Negative
Market Momentum
0.03
Positive
48.62
Neutral
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BLRX, the sentiment is Negative. The current price of 1.9 is below the 20-day moving average (MA) of 2.80, below the 50-day MA of 2.29, and below the 200-day MA of 5.79, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 48.62 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BLRX.
Bioline Rx Risk Analysis
Bioline Rx disclosed 43 risk factors in its most recent earnings report. Bioline Rx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioline Rx Peers Comparison
Overall Rating
UnderperformOutperform
Sector (66)
Financial Indicators
Performance Comparison
IL:BLRX
Bioline Rx
2.60
-12.40
-82.67%
IL:CANF
Can Fite Bio
1.20
-1.90
-61.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.